- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-175/22: Action brought on 4 April 2022 — Novartis v EUIPO — AstraZeneca (BREZTRI)
ECLI:EU:UNKNOWN:62022TN0175
62022TN0175
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
23.5.2022
Official Journal of the European Union
C 207/53
(Case T-175/22)
(2022/C 207/70)
Language in which the application was lodged: English
Parties
Applicant: Novartis AG (Basel, Switzerland) (represented by: A. Nordemann-Schiffel, lawyer)
Defendant: European Union Intellectual Property Office (EUIPO)
Other party to the proceedings before the Board of Appeal: AstraZeneca AB (Södertälje, Sweden)
Details of the proceedings before EUIPO
Proprietor of the trade mark at issue: Other party to the proceedings before the Board of Appeal
Trade mark at issue: European Union word mark BREZTRI — European Union trade mark No 17 816 687
Procedure before EUIPO: Cancellation proceedings
Contested decision: Decision of the Second Board of Appeal of EUIPO of 21 January 2022 in Case R 737/2021-2
Form of order sought
The applicant claims that the Court should:
—annul the contested decision;
—order EUIPO to pay the costs.
Pleas in law
—Infringement of Article 27(3)(b) of Commission Delegated Regulation (EU) 2017/1430;
—Infringement of Article 60(1)(a) in conjunction with Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.